Showing 1011-1020 of 1560 results for "".
- Beyond Antibodies: Unveiling New Dimensions of Immune Response and Therapyhttps://reachmd.com/news/beyond-antibodies-unveiling-new-dimensions-of-immune-response-and-therapy/2483252/Seasonal influenza is continuing to drive hospitalizations and deaths while ARDS is persistently straining critical care capacity, focusing clinicians on immune mechanisms that are actively informing prevention and treatment right now. The same B cell mechanisms that
- Natera’s Signatera Data: Advancements in Lung Cancer Profilinghttps://reachmd.com/news/nateras-signatera-data-advancements-in-lung-cancer-profiling/2483102/As lung cancer continues to rank as the most commonly diagnosed cancer worldwide, the push for more precise, personalized diagnostics remains urgent. In that context, Natera, Inc.—a leader in cell-free DNA technology and precision medicine—
- Revolutionizing NSCLC Treatment: The Power of Precision Diagnostics and AIhttps://reachmd.com/news/revolutionizing-nsclc-treatment-the-power-of-precision-diagnostics-and-ai/2482972/The landscape of non-small cell lung cancer (NSCLC) is undergoing rapid transformation with the integration of genetic profiling and artificial intelligence, offering new opportunities for more personalized care. The same genetic profiling that enhances targeted ther
- Unlocking the Potential of Autoantibodies in Cancer Immunotherapyhttps://reachmd.com/news/unlocking-the-potential-of-autoantibodies-in-cancer-immunotherapy/2475879/Advancements in personalized medicine and immunotherapy are opening new possibilities in cancer treatment. However, predicting which patients will respond remains challenging. Autoantibodies have become important indicators of patient response, and ensuring that engineered immune cells rema
- Overcoming Chemotherapy Resistance in Bladder Cancer: The Role of Inflammatory Pathways and TRIM Proteinshttps://reachmd.com/news/overcoming-chemotherapy-resistance-in-bladder-cancer-the-role-of-inflammatory-pathways-and-trim-proteins/2475738/Bladder cancer remains challenging to treat, as it can initiate an inflammatory response that strengthens tumor cell resilience to chemotherapy. Resisting chemotherapy has emerged as one of the greatest obstacles in bladder
- Balancing Immunotherapy and Comorbidities in NSCLChttps://reachmd.com/news/balancing-immunotherapy-comorbidities-in-nsclc/2475560/Immunotherapy is revolutionizing lung cancer treatment, particularly for non-small cell lung cancer (NSCLC), but its full potential can be undermined by routine corticosteroid use and complex comorbidities that demand nuanced management strat
- Targeting HIV-1 Vpr: Disrupting Viral Replication for New Antiviral Strategieshttps://reachmd.com/news/targeting-hiv-1-vpr-disrupting-viral-replication-for-new-antiviral-strategies/2475569/As HIV-1 continues to challenge global health, new insights into the viral protein R (Vpr) reveal it as a pivotal influencer of replication in T cells and macrophages, posing both challenges and opportunities for treatment advancements. <
- Evolving Insights in Lung Cancer Surgery: Recurrence Patterns and Emerging Therapieshttps://reachmd.com/news/evolving-insights-in-lung-cancer-surgery-recurrence-patterns-and-emerging-therapies/2475265/Thoracic surgeons continually grapple with balancing the extent of resection against functional preservation to minimize recurrence rates and optimize outcomes in early-stage non–small cell lung cancer (NSCLC). Lung cancer surgery rema
- Emerging Biomarkers and Genetic Insights Revolutionize Early Parkinson's Detectionhttps://reachmd.com/news/emerging-biomarkers-and-genetic-insights-revolutionize-early-parkinsons-detection/2475232/Overlooked until now, volatile compounds in ear wax and circulating T cell signatures are reshaping our approach to early Parkinson's disease detection, while genetic parallels from obsessive-compulsive disorder studies and prognostic insight
- The Dawn of Immunotherapy in Head and Neck Cancer: Pembrolizumab's Rolehttps://reachmd.com/news/the-dawn-of-immunotherapy-in-head-and-neck-cancer-pembrolizumabs-role/2475186/Despite aggressive multimodal strategies, survival gains in locally advanced head and neck squamous cell carcinoma have been marginal, with reports indicating an average annual improvement of only 0.28%, highlighting the need for new therapeu